Free Trial
OTCMKTS:VYNT

Vyant Bio (VYNT) Stock Price, News & Analysis

Vyant Bio logo
$0.19 +0.01 (+7.78%)
As of 12/29/2023

About Vyant Bio Stock (OTCMKTS:VYNT)

Key Stats

Today's Range
$0.18
$0.20
50-Day Range
$0.19
$0.19
52-Week Range
$0.14
$1.58
Volume
19,100 shs
Average Volume
161,822 shs
Market Capitalization
$1.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey.

Receive VYNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vyant Bio and its competitors with MarketBeat's FREE daily newsletter.

VYNT Stock News Headlines

Vyant Bio Inc VYNT
Trump Makes Major Crypto Announcement
Pay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift all boats equally. They're wrong. One project stands to benefit more than any other – not by accident, but seemingly by design.
Vyant Bio Provides Update on Winddown Activities
See More Headlines

VYNT Stock Analysis - Frequently Asked Questions

Vyant Bio's stock was trading at $0.1940 at the start of the year. Since then, VYNT stock has increased by 0.0% and is now trading at $0.1940.
View the best growth stocks for 2025 here
.

Vyant Bio, Inc. (OTCMKTS:VYNT) released its quarterly earnings results on Thursday, November, 11th. The company reported ($0.75) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.75). The business earned $1.51 million during the quarter, compared to analysts' expectations of $2.19 million. Vyant Bio had a negative trailing twelve-month return on equity of 151.82% and a negative net margin of 3,474.81%.
Read the conference call transcript
.

Shares of Vyant Bio reverse split on Wednesday, November 2nd 2022. The 1-5 reverse split was announced on Wednesday, November 2nd 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 2nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Shares of VYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vyant Bio investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Alphabet (GOOG) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
11/11/2021
Today
6/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Medical laboratories
Sub-Industry
Healthcare
Current Symbol
OTCMKTS:VYNT
Employees
30
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$22.69 million
Net Margins
-3,474.81%
Pretax Margin
-3,281.86%

Debt

Sales & Book Value

Annual Sales
$670 thousand
Price / Cash Flow
N/A
Book Value
$1.69 per share
Price / Book
0.11

Miscellaneous

Free Float
5,724,000
Market Cap
$1.23 million
Optionable
Not Optionable
Beta
1.73
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (OTCMKTS:VYNT) was last updated on 6/7/2025 by MarketBeat.com Staff
From Our Partners